Northwest Biotherapeutics, Inc.
NWBO
$0.21
-$0.004-1.87%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.60M | 1.65M | 1.34M | 1.93M | 2.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.60M | 1.65M | 1.34M | 1.93M | 2.08M |
| Cost of Revenue | 31.82M | 30.89M | 28.81M | 27.73M | 29.63M |
| Gross Profit | -30.22M | -29.25M | -27.48M | -25.80M | -27.54M |
| SG&A Expenses | 32.93M | 32.93M | 30.81M | 29.71M | 31.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.75M | 63.82M | 59.62M | 57.44M | 60.63M |
| Operating Income | -63.15M | -62.18M | -58.29M | -55.51M | -58.54M |
| Income Before Tax | -74.47M | -78.62M | -75.20M | -67.54M | -76.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.47 | -78.62 | -75.20 | -67.54 | -76.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.47M | -78.62M | -75.20M | -67.54M | -76.92M |
| EBIT | -63.15M | -62.18M | -58.29M | -55.51M | -58.54M |
| EBITDA | -61.42M | -60.47M | -56.67M | -53.98M | -57.13M |
| EPS Basic | -0.06 | -0.07 | -0.07 | -0.06 | -0.07 |
| Normalized Basic EPS | -0.03 | -0.04 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | -0.08 | -0.08 | -0.07 | -0.06 | -0.07 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.04 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 4.82B | 4.70B | 4.59B | 4.48B | 4.38B |
| Average Diluted Shares Outstanding | 4.82B | 4.70B | 4.59B | 4.48B | 4.38B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
